Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Working Capital Changes: 2009-2020

Historic Other Working Capital Changes for Tg Therapeutics (TGTX) over the last 12 years, with Dec 2020 value amounting to -$2.3 million.

  • Tg Therapeutics' Other Working Capital Changes rose 19.72% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.0 million, marking a year-over-year increase of 90.05%. This contributed to the annual value of -$2.3 million for FY2020, which is 63.08% down from last year.
  • As of FY2020, Tg Therapeutics' Other Working Capital Changes stood at -$2.3 million, which was down 63.08% from -$1.4 million recorded in FY2019.
  • In the past 5 years, Tg Therapeutics' Other Working Capital Changes ranged from a high of $2.7 million in FY2017 and a low of -$3.6 million during FY2016.
  • For the 3-year period, Tg Therapeutics' Other Working Capital Changes averaged around -$667,667, with its median value being -$1.4 million (2019).
  • In the last 5 years, Tg Therapeutics' Other Working Capital Changes slumped by 214.79% in 2016 and then skyrocketed by 174.75% in 2017.
  • Yearly analysis of 5 years shows Tg Therapeutics' Other Working Capital Changes stood at -$3.6 million in 2016, then surged by 174.75% to $2.7 million in 2017, then tumbled by 38.54% to $1.6 million in 2018, then crashed by 184.49% to -$1.4 million in 2019, then slumped by 63.08% to -$2.3 million in 2020.